Dipyridamole
Platelet Aggregation Inhibitors Excl. Heparin
Sold as PERSANTINE
- Drug class
- Platelet Aggregation Inhibitors Excl. Heparin
- Availability
- Prescription only
- Routes
- Intravenous, Oral
- Markets covered
- 3
- Products on record
- 16
- FDA reports (12 mo)
- 71
Overview
Dipyridamole is an active pharmaceutical ingredient in the Platelet Aggregation Inhibitors Excl. Heparin group (B01AC). The information below is compiled per regulator from the product labels on record, with direct links to the original documents.
Regulatory status by market
| Market | Regulator | Products | Last revision |
|---|---|---|---|
| GB United Kingdom | MHRA | 13 | May 15, 2026 |
| CA Canada | Health Canada | 2 | March 22, 2025 |
| US United States | FDA | 1 | September 16, 2023 |
GBUnited Kingdom· MHRA
13 products
Uses
1. As an adjunct to oral anti-coagulation for prophylaxis of thromboembolism associated with prosthetic heart valves. 2. In combination with aspirin for: a. Prophylaxis of deep venous thrombosis as an alternative to subcutaneous heparin, other than in hip surgery.
b. Prophylaxis of recurrent venous thrombosis resistant to oral anti- coagulation. c. Prophylaxis of occlusion following prosthetic arterial grafts and coronary artery bypass grafts.
How to take
CACanada· Health Canada
2 products
Uses
PERSANTINE (5 mg/mL dipyridamole) is indicated for: • intravenous use to induce pharmacologic vasodilation for myocardial perfusion imaging. 1 Pediatrics Pediatrics (< 18 years of age): No data are available to Health Canada; therefore, Health Canada has not authorized an indication for pediatric use.
How to take
USUnited States· FDA
1 product
Uses
INDICATIONS AND USAGE
Dipyridamole tablets are indicated as an adjunct to coumarin anticoagulants in the prevention of postoperative thromboembolic complications of cardiac valve replacement.
How to take
Drug interactions
Known interactions involving Dipyridamole. Select one for details. This list is informational and not a complete interaction checker.
Showing 240 of 293. Type above to find a specific drug.
Interaction data compiled from DDInter (academic, CC-BY). Severity classification only - this is not a complete interaction checker and not medical advice.
Sources & citations
- [1]MHRA (UK) · PL334140042 · revised November 21, 2025
- [2]Health Canada (DPD) · 00637734 · revised March 22, 2025
- [3]FDA DailyMed · 004bada0-dbf7-4a… · revised September 16, 2023 [PDF]
- [4]OpenFDA adverse-event reports (US), 12 months ending June 4, 2026.
Information on this page is compiled from public regulatory records. Drugvu is not affiliated with any regulator or pharmaceutical manufacturer. This is not medical advice. Always consult a qualified healthcare professional.